How would you manage a patient with high risk triple negative breast cancer with metastatic disease after recent adjuvant AC-T?

If she relapsed within 12 months of her adjuvant paclitaxel, then I would consider her TNBC taxane resistant. These patients weren't enrolled in Impassion130 and many first line trials exclude patients with short DFI. If a trial is available, consider it whenever possible. I would do BRCA germline t...